Product nameAnti-BTK (phospho Y550) antibody
See all BTK primary antibodies
DescriptionRabbit polyclonal to BTK (phospho Y550)
SpecificityDetects endogenous levels of BTK only when phosphorylated at tyrosine 550.
Tested applicationsSuitable for: ELISA, WB, ICC/IFmore details
Species reactivityReacts with: Mouse, Human
Synthetic phosphopeptide derived from human BTK around the phosphorylation site of tyrosine 550 (D-E-YP-T-S).
- WB: Extracts from HeLa cells treated with H2O2. ICC/IF: formaldehyde fixed DU145 cells.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol, 0.87% Sodium chloride
Without Mg+2 and Ca+2
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab52192 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/1000. Detects a band of approximately 76 kDa (predicted molecular weight: 76 kDa).|
|ICC/IF||Use a concentration of 10 µg/ml.|
FunctionPlays a crucial role in B-cell ontogeny. Transiently phosphorylates GTF2I on tyrosine residues in response to B-cell receptor cross-linking. Required for the formation of functional ARID3A DNA-binding complexes.
Involvement in diseaseDefects in BTK are the cause of X-linked agammaglobulinemia (XLA) [MIM:300755]; also known as X-linked agammaglobulinemia type 1 (AGMX1) or immunodeficiency type 1 (IMD1). XLA is a humoral immunodeficiency disease which results in developmental defects in the maturation pathway of B-cells. Affected boys have normal levels of pre-B-cells in their bone marrow but virtually no circulating mature B-lymphocytes. This results in a lack of immunoglobulins of all classes and leads to recurrent bacterial infections like otitis, conjunctivitis, dermatitis, sinusitis in the first few years of life, or even some patients present overwhelming sepsis or meningitis, resulting in death in a few hours. Treatment in most cases is by infusion of intravenous immunoglobulin.
Defects in BTK may be the cause of X-linked hypogammaglobulinemia and isolated growth hormone deficiency (XLA-IGHD) [MIM:307200]; also known as agammaglobulinemia and isolated growth hormone deficiency or Fleisher syndrome or isolated growth hormone deficiency type 3 (IGHD3). In rare cases XLA is inherited together with isolated growth hormone deficiency (IGHD).
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. TEC subfamily.
Contains 1 Btk-type zinc finger.
Contains 1 PH domain.
Contains 1 protein kinase domain.
Contains 1 SH2 domain.
Contains 1 SH3 domain.
modificationsAutophosphorylated on Tyr-223 and Tyr-551. Phosphorylation of Tyr-223 may create a docking site for a SH2 containing protein.
Cellular localizationCytoplasm. Membrane. Nucleus.
- Information by UniProt
- Agammaglobulinaemia tyrosine kinase antibody
- AGMX 1 antibody
- AGMX1 antibody
All lanes : Anti-BTK (phospho Y550) antibody (ab52192) at 1/500 dilution
Lane 1 : extracts from HeLa cells, treated with H2O2
Lane 2 : extracts from HeLa cells, treated with H2O2 with blocking peptide
Predicted band size: 76 kDa
Observed band size: 76 kDa
ICC/IF image of ab52192 stained DU145 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab52192 at 10µg/ml overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti- rabbit (ab96899) IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
This product has been referenced in:
- Jiang M et al. Potential efficacy and prognosis of silencing the CRLF2-mediated AKT/mTOR pathway in pediatric acute B-cell lymphoblastic leukemia. Oncol Rep 41:885-894 (2019). Read more (PubMed: 30535452) »
- Yim JH et al. Phosphoprotein profiles of candidate markers for early cellular responses to low-dose ?-radiation in normal human fibroblast cells. J Radiat Res 58:329-340 (2017). WB ; Human . Read more (PubMed: 28122968) »